CD34 and acute myeloid leukemia: The CD34+CD38− leukemia cell population holds leukemia stem cells (LSCs) accountable for therapy failure in acute myeloid leukemia (AML) and, therefore, new therapies are needed for eradicating LSCs without harming healthy hematopoietic stem cells (HSCs).